The PE Ratio as of November 2024 (TTM) for Cytokinetics, Incorporated (CYTK) is -9.13

According to Cytokinetics, Incorporated’s latest financial reports and current stock price. The company's current PE Ratio is -9.13. This represents a change of -25.35% compared to the average of -12.23 of the last 4 quarters.

Cytokinetics, Incorporated (CYTK) Historical PE Ratio (quarterly & annually)

How has CYTK PE Ratio performed in the past?

The mean historical PE Ratio of Cytokinetics, Incorporated over the last ten years is -5.95. The current -9.13 PE Ratio has changed 15.25% with respect to the historical average. Over the past ten years (40 quarters), CYTK's PE Ratio was at its highest in in the December 2016 quarter at 17.22. The PE Ratio was at its lowest in in the September 2020 quarter at -116.40.

Cytokinetics, Incorporated (CYTK) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cytokinetics, Incorporated PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cytokinetics, Incorporated (CYTK) Average PE Ratio

How has CYTK PE Ratio performed in the past?

The current PE Ratio of Cytokinetics, Incorporated (CYTK) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Cytokinetics, Incorporated (CYTK) PE Ratio vs. Peers

How is CYTK’s PE Ratio compared to its peers?

Cytokinetics, Incorporated’s PE Ratio is greater than DICE Therapeutics, Inc. (-22.94), greater than Edgewise Therapeutics, Inc. (-24.30), greater than Karuna Therapeutics, Inc. (-37.08), greater than Dyne Therapeutics, Inc. (-10.17), less than Stoke Therapeutics, Inc. (-6.11), less than Pliant Therapeutics, Inc. (-3.91), greater than Revolution Medicines, Inc. (-16.70), less than Relay Therapeutics, Inc. (-1.93), less than Black Diamond Therapeutics, Inc. (-1.96), less than Arvinas, Inc. (-6.04), less than Terns Pharmaceuticals, Inc. (-5.12), less than Amylyx Pharmaceuticals, Inc. (-1.38), less than Acumen Pharmaceuticals, Inc. (-1.74), less than Inozyme Pharma, Inc. (-1.84), less than X4 Pharmaceuticals, Inc. (-4.05), greater than Blueprint Medicines Corporation (-46.60),

Build a custom stock screener for Cytokinetics, Incorporated (CYTK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cytokinetics, Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cytokinetics, Incorporated (CYTK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cytokinetics, Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.